Spike protein mediated membrane fusion during SARS-CoV-2 infection

J Med Virol. 2023 Jan;95(1):e28212. doi: 10.1002/jmv.28212. Epub 2022 Oct 25.

Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to public health and has quickly become a global concern. The infection of SARS-CoV-2 begins with the binding of its spike protein to the receptor-angiotensin-converting enzyme 2 (ACE2), which, after a series of conformation changes, results in the fusion of viral-cell membranes and the release of the viral RNA genome into the cytoplasm. In addition, infected host cells can express spike protein on their cell surface, which will interact with ACE2 on neighboring cells, leading to cell membrane fusion and the formation of multinucleated cells or syncytia. Both viral entry and syncytia formation are mediated by spike-ACE2 interaction and share some common mechanisms of membrane fusion. Here in this review, we will summarize our current understanding of spike-mediated membrane fusion, which may shed light on future broad-spectrum antiviral development.

Keywords: antiviral agents; cell fusion; cellular effect; coronavirus; entry inhibitors; virus classification.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • COVID-19*
  • Humans
  • Membrane Fusion
  • Protein Binding
  • SARS-CoV-2 / metabolism
  • Spike Glycoprotein, Coronavirus / metabolism
  • Virus Internalization

Substances

  • Angiotensin-Converting Enzyme 2
  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus